The economics of preventive precision medicine

You don't wait for a jet engine to fail.

Instead, predictive maintenance helps identify potential problems before they become failures, allowing engineers to intervene earlier. The principle, of anticipating risk rather than simply reacting to it, is a simple one.

So why isn't healthcare more consistently built around the same principle?

Advances in predictive precision medicine are making it increasingly possible to identify and intervene. At Triple Helix Science, we focus on earlier, patient-first intervention.

But barriers still limit global adoption of this science, and the challenge is as much economic as it is scientific.

A healthcare system built on managing diseases

If we examine the revenue model of the global healthcare industry, a significant proportion is organized around managing diseases over a lifetime. Established reimbursement models, clinical pathways and commercial incentives have evolved around that reality.

The United States offers a striking illustration of the scale involved. The U.S. Centers for Disease Control and Prevention suggests 90 percent of the $5.3 trillion annual healthcare expenditures in the U.S. are for people with chronic and mental health conditions. 

That figure reflects the enormous burden of these conditions, but it does not, by itself, establish that long-term treatment is more profitable than prevention. It does, though, paint an interesting picture of the current system, and highlights the importance of finding more effective one-time interventions to prevent, delay or modify disease.

Economics plays a crucial role here, because existing models of disease management rely on long-term revenue streams to support research, development, and manufacturing costs. So we find ourselves at a crossroads, and the result is a fundamental tension in how we transform our concept of healthcare across both clinical and financial dimensions.

The science is advancing – can healthcare keep up?

Emerging therapies help illustrate why this question matters.

Life Biosciences, for example, is in Phase 1 clinical trials of its investigation into partial epigenetic reprogramming to address aspects of age-related tissue dysfunction. This early clinical work in optic neuropathies reflects a broader scientific ambition to explore whether biological processes associated with aging can be modified therapeutically. It is an early step in testing whether this approach could eventually help address forms of vision loss that current treatments cannot reverse, but success in this field could shift how we approach gene therapy when it comes to eye disease.

And of course, at Triple Helix Science, our work also explores the potential of biological reprogramming with a particular focus on the need to control how these processes are activated. Some of the pathways involved in restoring cellular function are also associated with cancer when their activity becomes excessive or poorly regulated. Understanding and managing those risks is central to developing approaches that could be both effective and safe.

These examples illustrate both the promise and the complexity of precision medicine. The aim is to move beyond managing established disease towards interventions that could alter disease risk or progression.

But scientific progress alone is not enough, but rather the question is whether healthcare systems can evolve quickly enough to evaluate, fund and deliver these approaches.

An opportunity to rethink the model

Countries with decades-old healthcare models, like the U.S. and the U.K., face the problem of speed, where systems are difficult to adapt. Competing budgetary priorities can also influence how quickly new approaches reach patients.

This is where emerging nations have an opportunity to approach this challenge differently. They may have more scope to design new care pathways around preventive and precision medicine, rather than adapting every innovation to systems built around established models of treatment. This ambition to build a curative, preventive medicine model would set a new global standard of care for everyone.

That opportunity should not be mistaken for an easy transition. When systems are so well established, we must acknowledge that unwinding them is extraordinarily challenging. Reinventing the wheel requires investment, robust regulation, specialist expertise and equitable access. Add a financial element, and there is little incentive to adopt one-time preventive interventions. 

Yet the possibility of redefining this new care pathway, rather than retrofitting every element of an existing model, deserves serious consideration.

Emerging economies could help demonstrate how healthcare systems can make earlier intervention more practical, accessible and sustainable while putting people first.

From managing disease to changing the trajectory

The true measure of progress in medicine is not the technology itself, but the difference it makes to people's lives. At Triple Helix Science, we strongly believe people deserve to see a shift in how we approach healthcare globally. By leveraging rigorous, clinically robust, and regulated precision medicine, we can.

We should also be prepared to rethink how we assess value, allocate resources and deliver care. In aviation, anticipating a problem only works if the systems are in place to act before failure occurs. Healthcare faces the same test because, although the science may increasingly allow us to intervene earlier, our models of funding and delivering care still need to evolve to make that possible.

The goal is not simply to treat disease differently. It is to change its trajectory – and improve the lives of the people at risk while raising the standard of care for everyone.